Hepatic angiosarcoma is a rare and aggressive form of liver cancer that develops in the cells lining blood vessels within the liver. Despite its rarity, accounting for only 0.1 to 2 percent of all primary liver cancers, it ranks as the third most common primary liver malignancy. The treatment approach depends on the stage of the disease, the extent of tumor spread, and the patient’s overall health condition. While standard therapies exist, ongoing research is exploring new treatment options through clinical trials, offering hope for improved outcomes in this challenging disease.

Understanding Treatment Goals for Hepatic Angiosarcoma

The primary aim when treating hepatic angiosarcoma is to remove or destroy the cancerous tissue while preserving as much healthy liver function as possible. Because this cancer develops in the cells that form the inner lining of blood vessels in the liver, it can spread quickly and aggressively throughout the organ and to other parts of the body. Treatment choices are carefully tailored to each person’s situation, considering factors such as the size and location of the tumor, whether the cancer has spread beyond the liver, and the individual’s ability to tolerate aggressive therapies.^[1]

Early detection plays a critical role in treatment success. Unfortunately, hepatic angiosarcoma often causes no symptoms in its early stages, or produces only vague complaints such as abdominal pain, weight loss, fatigue, or bloating that could be mistaken for many other conditions. By the time the disease is diagnosed, it may already be at an advanced stage, which limits treatment options. The aggressive nature of this cancer means that even with treatment, outcomes are often challenging, with many patients facing a median survival of around six months after diagnosis.^[9]

Medical societies and treatment guidelines recognize that hepatic angiosarcoma requires a coordinated approach involving multiple specialists, including surgeons, oncologists, radiologists, and pathologists. Standard treatments approved for use include surgical removal of the tumor when possible, along with chemotherapy and radiation therapy. At the same time, researchers are actively investigating new therapeutic approaches in clinical trials, testing innovative drugs and treatment combinations that may offer better results than current options.^[7]

Standard Treatment Approaches

Surgical resection, or the removal of the tumor through an operation, remains the cornerstone of treatment for hepatic angiosarcoma when the disease is detected early enough and the tumor is confined to a removable portion of the liver. The goal of surgery is to achieve what doctors call “negative margins,” meaning that no cancer cells are detected at the edges of the removed tissue. This complete removal offers the only realistic chance of long-term survival. During a hepatic resection, surgeons remove the part of the liver containing the tumor, relying on the liver’s remarkable ability to regenerate itself over time.^[9]

However, the majority of patients present with disease that has already spread too widely within the liver or to other organs, making them unsuitable candidates for surgery. In these cases, or when surgery is unable to remove all cancerous tissue, other treatment modalities become necessary. The decision about whether surgery is possible depends on detailed imaging studies, including CT scans, MRI, and sometimes PET scans, which help doctors understand the full extent of the disease before planning treatment.^[1]

Chemotherapy involves the use of powerful drugs designed to kill cancer cells or stop them from growing and dividing. For hepatic angiosarcoma, chemotherapy is often used when surgery is not possible, when the cancer has spread beyond the liver, or as an additional treatment after surgery to reduce the risk of recurrence. Various chemotherapy drugs and combinations have been tried in hepatic angiosarcoma, although no single regimen has emerged as a universally accepted standard. According to a study examining treatment outcomes at a major cancer center, approximately 71 percent of patients received systemic chemotherapy as part of their treatment plan.^[9]

The specific chemotherapy drugs chosen may include agents commonly used for soft tissue sarcomas, since hepatic angiosarcoma belongs to this broader category of cancers. Treatment typically involves cycles of drug administration, with periods of rest in between to allow the body to recover from side effects. The duration of chemotherapy varies depending on how well the cancer responds and how well the patient tolerates the treatment. Common side effects of chemotherapy include fatigue, nausea and vomiting, hair loss, increased risk of infection due to low white blood cell counts, and anemia. These side effects are temporary and usually resolve after treatment ends, although some may require additional medications to manage.^[9]

Radiation therapy uses high-energy beams to destroy cancer cells. While not commonly used as a primary treatment for hepatic angiosarcoma, radiation may play a role in certain situations. For example, when surgical removal of the tumor results in positive margins, meaning cancer cells remain at the edges of the removed tissue, radiation therapy may be directed at the surgical site to destroy any remaining cancer cells and reduce the risk of local recurrence. A case report described successful use of adjuvant radiotherapy following surgery with involved margins, contributing to long-term survival without further recurrence.^[19]

Another specialized approach involves transarterial embolization (TAE), a procedure particularly useful in emergency situations. Hepatic angiosarcomas have an extensive blood supply and can rupture, causing life-threatening internal bleeding. TAE involves threading a thin tube called a catheter through blood vessels to reach the arteries feeding the tumor, then blocking these vessels using special materials. This cuts off the tumor’s blood supply, causing it to shrink and stopping the bleeding. In one reported case, TAE was used successfully to control severe bleeding from a ruptured hepatic angiosarcoma, stabilizing the patient enough to later undergo surgical removal of the tumor.^[6]

Treatment in Clinical Trials

Given the poor outcomes associated with standard treatments for hepatic angiosarcoma, researchers are actively investigating new therapeutic approaches through clinical trials. These studies test promising drugs and treatment strategies to determine whether they can improve survival and quality of life for patients with this aggressive disease. Clinical trials proceed through different phases, each designed to answer specific questions about a new treatment’s safety and effectiveness.^[7]

Immunotherapy represents one of the most promising areas of investigation in hepatic angiosarcoma treatment. This approach harnesses the body’s own immune system to recognize and attack cancer cells. Unlike chemotherapy, which directly poisons cancer cells, immunotherapy works by removing the brakes that prevent immune cells from attacking tumors or by enhancing the immune system’s ability to find and destroy cancer cells. According to research from a major academic cancer center, approximately 29 percent of hepatic angiosarcoma patients received immunotherapy as part of their treatment.^[9]

Specific immunotherapy drugs that have shown promise in clinical studies include checkpoint inhibitors such as ipilimumab and nivolumab. These drugs work by blocking proteins on immune cells or cancer cells that normally prevent the immune system from attacking the tumor. By blocking these checkpoint proteins, the drugs essentially release the immune system to do its job. In the study mentioned above, three patients who received various treatments including the combination of ipilimumab and nivolumab demonstrated particularly improved survival compared to other patients in the study. One patient who underwent hepatic resection followed by this immunotherapy combination experienced notably extended survival.^[9]

The mechanism of action of checkpoint inhibitors involves complex interactions between cancer cells and immune cells. Cancer cells often display molecules on their surface that send “don’t attack me” signals to immune cells. Checkpoint inhibitors block these signals, allowing T cells, a type of white blood cell that fights infections and cancer, to recognize the cancer cells as foreign and destroy them. While this approach has revolutionized treatment for some cancers, its effectiveness in hepatic angiosarcoma is still being evaluated through ongoing clinical trials.^[7]

Clinical trials testing immunotherapy for hepatic angiosarcoma are generally Phase II or Phase III studies. Phase II trials focus on determining whether the treatment has an effect on the cancer, measuring outcomes such as tumor shrinkage, stabilization of disease, and how long patients live without their cancer worsening. Phase III trials compare the new treatment directly with the current standard treatment to determine whether the new approach offers better outcomes. Patients interested in participating in clinical trials for hepatic angiosarcoma can inquire with their oncology team about available studies. These trials may be conducted at specialized cancer centers in locations including the United States, Europe, and other regions around the world.^[7]

Beyond immunotherapy, researchers are also investigating other innovative approaches in early-phase clinical trials. These might include drugs that target specific molecular pathways involved in blood vessel formation, since angiosarcomas originate from cells that line blood vessels. Such targeted therapies work by interfering with specific molecules needed for tumor growth and blood vessel development. While specific drug names and code designations for experimental compounds were not detailed in the available research, the general approach involves identifying unique characteristics of angiosarcoma cells and developing treatments that exploit these differences between cancer cells and normal cells.^[7]

Patient eligibility for clinical trials depends on several factors. These typically include the stage of the disease, previous treatments received, overall health status, and how well the liver and other organs are functioning. Some trials specifically seek patients who have not yet received any treatment, while others focus on those whose cancer has progressed despite standard therapy. Participation in a clinical trial means receiving close monitoring and frequent assessments to track both the effectiveness of the treatment and any side effects that develop. While clinical trials offer access to potentially beneficial new treatments, they also involve uncertainty, as the treatments are still being studied and may not work better than existing options.^[9]

Most common treatment methods

• Surgical resection
  • Complete removal of the tumor-containing portion of the liver with negative margins offers the only curative option
  • May include right hemihepatectomy (removal of the right half of the liver) or segmentectomy (removal of specific liver segments)
  • Effectiveness depends on early detection before the cancer spreads widely
  • Only feasible in approximately 14 percent of patients due to advanced disease at diagnosis
• Chemotherapy
  • Used when surgery is not possible or as additional treatment after surgery
  • Approximately 71 percent of patients receive systemic chemotherapy
  • Various drug combinations based on regimens used for soft tissue sarcomas
  • Given in cycles with rest periods to allow recovery from side effects
• Immunotherapy
  • Checkpoint inhibitors such as ipilimumab and nivolumab show promise in clinical studies
  • Works by enabling the immune system to recognize and attack cancer cells
  • Approximately 29 percent of patients receive immunotherapy
  • Some patients receiving this treatment have demonstrated improved survival outcomes
• Radiation therapy
  • Used primarily as adjuvant treatment after surgery with positive margins
  • Helps destroy remaining cancer cells at the surgical site
  • Can reduce risk of local recurrence when combined with surgical resection
• Transarterial embolization
  • Emergency procedure to control bleeding from tumor rupture
  • Blocks blood vessels feeding the tumor using a catheter-based approach
  • Can stabilize patients for potential subsequent surgical treatment
  • Used in 15 to 27 percent of patients who experience spontaneous tumor rupture